Professor Steven Nissen, Cleveland Clinic, Ohio, USA, reviews progress with zerlasiran, including the Phase 1 APOLLO single and multiple ascending dose study in patients with elevated Lp(a) (≥ 150 nmol/L), and the Phase 2 ALPACAR trial in patients at high risk of atherosclerotic cardiovascular disease and with elevated Lp(a) > 125 nmol/L
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)